| Wang, Qing |
NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults |
|
|
| Completed | 4 | 131650 | RoW | Experimental Group, CoronaVac | Sinovac Research and Development Co., Ltd. | COVID-19 | 01/23 | 08/23 | | |
NCT04992208: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents |
|
|
| Completed | 4 | 31041 | RoW | Experimental Group, CoronaVac | Sinovac Life Sciences Co., Ltd. | COVID-19 | 03/23 | 08/23 | | |
NCT05058040: A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971) |
|
|
| Active, not recruiting | 4 | 2500 | RoW | Sodium Oligomannate Capsules | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 04/25 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
CTP-MCVF-003, NCT06226714: A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds |
|
|
| Active, not recruiting | 3 | 840 | RoW | MCV4, MPSV4 | CanSino Biologics Inc. | Meningococcal Meningitis | 10/24 | 10/24 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
| Zhang, Jun |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT04782895: Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age |
|
|
| Completed | 3 | 488 | RoW | Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9 | Xiamen University, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Cervical Cancer, Condylomata Acuminata | 05/22 | 07/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT05056402: An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old |
|
|
| Active, not recruiting | 3 | 1382 | RoW | 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli) | Xiamen Ophthalmology Center Affiliated to Xiamen University, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Cervical Cancer, Condylomata Acuminata | 12/25 | 12/25 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT04537156: Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) |
|
|
| Active, not recruiting | 3 | 9327 | RoW | Nonavalent HPV vaccine, Bivalent HPV vaccine | Xiamen University, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata | 12/27 | 12/27 | | |
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy |
|
|
| Recruiting | 2/3 | 90 | RoW | Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
ALTER-G-001, NCT05262335: Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis |
|
|
| Recruiting | 2 | 116 | RoW | Anlotinib + Oxaliplatin + Capecitabine, Anlotinib + Cisplatin + Paclitaxel/ Docetaxel, Anlotinib + Standard first-line chemotherapy | Ruijin Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Gastrointestinal Tumors | 12/23 | 12/24 | | |
NCT02710851: Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine |
|
|
| Active, not recruiting | 2 | 640 | NA | low dosage HPV Vaccine(1:1), low dosage HPV Vaccine(1:2), high dosage HPV Vaccine(1:1), Hepatitis E vaccine,Hecolin® | Jun Zhang, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Condylomata Acuminata | 12/23 | 12/23 | | |
ACHIEVE, NCT04808752: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases |
|
|
| Active, not recruiting | 2 | 63 | RoW | Almonertinib, Investigational Product | Zhejiang Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 06/24 | 07/24 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
| Not yet recruiting | 2 | 40 | US | Cabozantinib, Cabometyx, Atezolizumab, Tecentriq | Jun Zhang, MD, PhD, Exelixis, Genentech, Inc. | Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC | 06/26 | 06/28 | | |
| Recruiting | 2 | 90 | Europe, US, RoW | Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin | Mirati Therapeutics Inc. | Advanced NSCLC, Metastatic Lung Cancer | 06/26 | 12/26 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT04440735: A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 125 | US | DSP107, Atezolizumab | Kahr Medical | Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer | 09/25 | 09/25 | | |
| Recruiting | 1/2 | 404 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 04/26 | 10/26 | | |
NCT05068856: A Study of HRS2543 in Patients With Advanced Tumors |
|
|
| Terminated | 1 | 10 | RoW | HRS2543 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Tumors | 05/24 | 05/24 | | |
NCT05537987: Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 30 | US | ICP-723 | InnoCare Pharma Inc. | Advanced Solid Tumors | 11/23 | 07/24 | | |
NCT04911166: Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy |
|
|
| Suspended | 1 | 13 | US | Atezolizumab and Interleukin-12 Gene Therapy | The Methodist Hospital Research Institute, Genentech, Inc. | Non-small Cell Lung Cancer | 08/24 | 03/25 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT05911217: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer |
|
|
| Recruiting | 1 | 20 | RoW | CT041 autologous CAR T-cell injection, Single Group Assignment | CARsgen Therapeutics Co., Ltd., Fudan University | Pancreatic Cancer | 12/26 | 12/26 | | |
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis |
|
|
| Completed | N/A | 260 | RoW | drug-coated balloon Catheter | B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, In Stent Restenosis | 07/22 | 08/22 | | |
NCT06197802: Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women |
|
|
| Active, not recruiting | N/A | 392 | RoW | Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9 | Xiamen University, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Cervical Cancer, Condylomata Acuminata | 03/25 | 03/25 | | |
| Recruiting | N/A | 25 | US | Standard of care immune checkpoint inhbitors | Jun Zhang, MD, PhD, Nilogen Oncosystems | Lung Cancer, NSCLC, NSCLC Stage IV | 01/26 | 02/27 | | |
HPV-PRO-006-4, NCT06243666: Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls |
|
|
| Not yet recruiting | N/A | 2188 | RoW | Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli), No intervention | Xiamen University, Xiamen Innovax Biotech Co., Ltd, Center for Disease Control and Prevention, Sheyang County, Yancheng City, Jiangsu Province, China | Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection | 12/26 | 12/26 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Li, Yuhua |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) |
|
|
| Recruiting | 1 | 108 | RoW | MRG001 | Shanghai Miracogen Inc. | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | 10/22 | 10/23 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT06450067: Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia |
|
|
| Recruiting | N/A | 200 | RoW | | Juventas Cell Therapy Ltd. | B-cell Acute Lymphoblastic Leukemia | 06/26 | 06/29 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
| Tu, Sanfang |
NCT05365100: A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL |
|
|
| Withdrawn | 1/2 | 174 | RoW | BN102, AS-1763 | BioNova Pharmaceuticals (Shanghai) LTD. | CLL/SLL, NHL | 07/24 | 07/24 | | |
NCT05607498: First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma |
|
|
| Recruiting | 1 | 150 | RoW | EMB07 | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma | 10/25 | 03/26 | | |
| Contact, Site Public |
| Completed | 4 | 50 | RoW | ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Hemophilia A | 02/23 | 02/23 | | |
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy |
|
|
| Completed | 4 | 4 | US | Digital Engagement Application (GD App), No Intervention | Takeda | Gaucher Disease | 02/23 | 02/23 | | |
| Active, not recruiting | 4 | 200 | US | CDPATH™, PROSPECT, Blood Draw | Takeda | Crohn's Disease | 10/25 | 06/26 | | |
| Recruiting | 4 | 80 | RoW | Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M | Takeda, Takeda | Central Precocious Puberty | 05/25 | 05/25 | | |
| Completed | 4 | 5 | RoW | Elaprase, Idursulfase | Takeda, Takeda Biopharmaceuticals India Pvt. Ltd. | Hunter Syndrome | 04/24 | 04/24 | | |
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
|
|
| Completed | 4 | 10 | RoW | Brentuximab vedotin, SGN-35 | Takeda | T-Cell Lymphoma | 08/24 | 08/24 | | |
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India |
|
|
| Active, not recruiting | 4 | 5 | RoW | Replagal | Shire | Fabry Disease | 10/26 | 11/26 | | |
TAK-113-4002, NCT06562543: A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer |
|
|
| Recruiting | 4 | 78 | US | Fruquintinib, Fruzaqla™ | Takeda | Colorectal Cancer | 02/28 | 02/28 | | |
| Active, not recruiting | 4 | 288 | Europe, US | Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo | Shire, Takeda Development Center Americas, Inc. | Attention Deficit Hyperactivity Disorder | 06/27 | 06/27 | | |
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) |
|
|
| Recruiting | 4 | 5 | US | ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG) | Takeda, Takeda Development Center Americas, Inc. | Mucopolysaccharidosis (MPS), Hunter Syndrome | 07/28 | 07/28 | | |
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |
|
|
| Recruiting | 4 | 150 | Canada, US | Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara | Takeda | Crohn's Disease | 06/27 | 06/27 | | |
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) |
|
|
| Recruiting | 4 | 65 | Canada, US | Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550 | Takeda | Ulcerative Colitis | 07/27 | 07/27 | | |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Terminated | 3 | 17 | Europe, Canada | REPLAGAL, SHP675 | Shire | Fabry Disease | 12/22 | 12/22 | | |
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor |
|
|
| Completed | 3 | 73 | Europe, Canada, Japan, US | Lanadelumab, DX-2930, SHP643, TAK-743 | Shire, Takeda Development Center Americas, Inc. | Angioedema | 05/23 | 05/23 | | |
| Completed | 3 | 51 | Europe, Japan, US | BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Thrombotic Thrombocytopenic Purpura (TTP) | 12/23 | 05/24 | | |
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) |
|
|
| Active, not recruiting | 3 | 38 | Europe, US, RoW | rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease (VWD) | 03/25 | 03/25 | | |
| Completed | 3 | 270 | Europe, Canada, Japan, US, RoW | Placebo, Soticlestat, TAK-935 | Takeda | Lennox Gastaut Syndrome (LGS) | 01/24 | 01/24 | | |
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) |
|
|
| Recruiting | 3 | 50 | Europe, Canada, US | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo | Takeda | Alpha1-Antitrypsin Deficiency | 08/28 | 08/28 | | |
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) |
|
|
| Recruiting | 3 | 34 | Europe, US, RoW | von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease | 01/25 | 01/25 | | |
| Completed | 3 | 144 | Europe, Canada, Japan, US, RoW | Soticlestat, TAK-935, Placebo | Takeda | Dravet Syndrome (DS) | 04/24 | 04/24 | | |
TAK-935-3004, NCT06422377: A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine |
|
|
| Terminated | 3 | 1 | Europe | Soticlestat, TAK-935 | Takeda | Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | 08/24 | 08/24 | | |
| Completed | 3 | 20 | RoW | REPLAGAL, Agalsidase Alfa, TAK-675 | Takeda, Takeda Development Center Americas, Inc | Fabry Disease | 01/24 | 01/24 | | |
| Completed | 3 | 20 | RoW | Lanadelumab, SHP643, TAKHZYRO, TAK-743, DX-2930, Lanadelumab Injection | Takeda, Takeda | Hereditary Angioedema (HAE) | 11/23 | 11/23 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
Vedolizumab-3041, NCT06443502: A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis |
|
|
| Recruiting | 3 | 30 | Europe, RoW | Vedolizumab, Entyvio, MLN0002, Kynteles, Concomitant Antibiotic Therapy | Takeda | Pouchitis | 12/29 | 12/29 | | |
| Active, not recruiting | 3 | 480 | RoW | TDV, TAK-003, Placebo | Takeda, Takeda | Healthy Volunteers | 05/25 | 05/25 | | |
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease (CD) | 11/24 | 11/24 | | |
| Completed | 3 | 20 | RoW | Velaglucerase Alfa, VPRIV | Takeda, Takeda | Gaucher Disease | 08/24 | 08/24 | | |
NCT05707351: A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A |
|
|
| Completed | 3 | 37 | RoW | Adynovate, Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol | Takeda | Hemophilia A | 09/24 | 09/24 | | |
| Recruiting | 3 | 396 | Canada, US | Vedolizumab, Entyvio, MLN0002, KYNTELES, Upadacitinib, Rinvoq, Placebo | Takeda | Crohn's Disease | 06/27 | 08/28 | | |
NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections |
|
|
| Not yet recruiting | 3 | 20 | RoW | Maribavir, TAK-620 | Takeda | Cytomegalovirus (CMV) | 02/27 | 02/27 | | |
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study |
|
|
| Recruiting | 3 | 700 | US | Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806 | SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC | Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | 03/25 | 03/28 | | |
| Recruiting | 3 | 20 | Europe, Japan, RoW | Darvadstrocel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 06/25 | 12/25 | | |
| Recruiting | 3 | 288 | Europe, Canada, US, RoW | RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide | RayzeBio, Inc., RayzeBio, Inc. | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | 12/25 | 07/28 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
| Active, not recruiting | 3 | 121 | Europe, Canada, Japan, US, RoW | Vedolizumab, MLN0002, ENTYVIO, KYNTELES | Takeda, Takeda Development Center Americas, Inc. | Colitis, Ulcerative | 08/25 | 08/25 | | |
| Terminated | 3 | 175 | US | Prucalopride, TAK-555, Prucalopride succinate, Placebo | Takeda, Takeda Development Center Americas, Inc. | Constipation | 11/23 | 11/23 | | |
| Recruiting | 3 | 328 | Europe, Canada, US | TAK-330, SOC 4F-PCC | Takeda, Takeda Development Center Americas, Inc. | Coagulation Disorder | 04/28 | 04/28 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | Soticlestat, TAK-935 | Takeda | Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS) | 05/26 | 05/26 | | |
NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura |
|
|
| Recruiting | 3 | 77 | Europe, Japan, US, RoW | TAK-755, rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930 | Takeda, Takeda Development Center Americas, Inc., Shire | Thrombotic Thrombocytopenic Purpura (TTP) | 03/27 | 03/27 | | |
TAK-620-2004, NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) |
|
|
| Active, not recruiting | 3 | 80 | Europe, Japan, US, RoW | Maribavir, TAK-620 | Takeda, Takeda Development Center Americas, Inc. | Cytomegalovirus (CMV) | 01/27 | 01/27 | | |
NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer |
|
|
| Recruiting | 3 | 408 | RoW | Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine | GC Cell Corporation | Pancreatic Ductal Adenocarcinoma | 12/26 | 06/27 | | |
| Active, not recruiting | 3 | 354 | US | Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac | SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc. | Colorectal Neoplasms | 02/27 | 02/32 | | |
| Recruiting | 3 | 24 | Europe, US | Recombinant von Willebrand Factor (rVWF), TAK-577, Vonicog Alfa, ADVATE, Recombinant Factor VIII (rFVIII), Octocog Alfa | Takeda, Takeda Development Center Americas, Inc. | Von Willebrand Disease (VWD) | 04/30 | 04/30 | | |
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein |
|
|
| Recruiting | 3 | 160 | Europe, Canada, US, RoW | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride | Takeda, Takeda Development Center Americas, Inc. | Alpha1-Antitrypsin Deficiency | 03/27 | 03/29 | | |
| Recruiting | 3 | 39 | US | TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., SC Investigational Needle Sets | Takeda, Takeda Development Center Americas, Inc., Baxalta Innovations GmbH, now part of Takeda | Primary Immunodeficiency Diseases (PID) | 01/29 | 01/29 | | |
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial |
|
|
| Recruiting | 3 | 1031 | Canada, US | Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc. | Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma | 01/28 | 05/35 | | |
|
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis |
|
|
| Recruiting | 3 | 402 | RoW | Vedolizumab IV, Placebo | Takeda | Moderately to Severely Active Ulcerative Colitis | 05/28 | 07/28 | | |
